Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CELECOXIB | 100MG | CAPSULE | Resolved | 2021-07-05 | 2022-01-31 | 141840 |
| APO-CELECOXIB | 200MG | CAPSULE | Resolved | 2021-08-03 | 2021-09-27 | 143397 |
| APO-CELECOXIB | 100MG | CAPSULE | Resolved | 2017-05-10 | 2017-11-20 | 9951 |
| APO-CELECOXIB | 100MG | CAPSULE | Resolved | 2024-06-27 | 2024-08-09 | 231490 |
| APO-CELECOXIB | 100MG | CAPSULE | Resolved | 2024-10-24 | 2024-11-22 | 241078 |
| APO-CELECOXIB | 200MG | CAPSULE | Resolved | 2024-11-29 | 2024-12-13 | 244206 |
| APO-CELECOXIB | 100MG | CAPSULE | Resolved | 2024-12-05 | 2025-01-24 | 244910 |
| APO-CELECOXIB | 200MG | CAPSULE | Resolved | 2023-02-23 | 2023-03-02 | 185471 |
| APO-CELECOXIB | 100MG | CAPSULE | Resolved | 2018-04-10 | 2018-08-02 | 45334 |
| APO-CELECOXIB | 100MG | CAPSULE | Resolved | 2018-08-21 | 2018-11-15 | 58583 |
| APO-CELECOXIB | 200MG | CAPSULE | Resolved | 2018-08-21 | 2018-11-02 | 58586 |
| APO-CELECOXIB | 200MG | CAPSULE | Resolved | 2021-01-08 | 2021-02-10 | 131142 |
| APO-CELECOXIB | 100MG | CAPSULE | Resolved | 2021-01-18 | 2021-02-09 | 131815 |
| APO-CELECOXIB | 100MG | CAPSULE | Resolved | 2021-03-05 | 2021-03-15 | 135153 |
| APO-CELECOXIB | 200MG | CAPSULE | Resolved | 2021-03-05 | 2021-03-15 | 135156 |
| APO-CELECOXIB | 200MG | CAPSULE | Resolved | 2017-09-26 | 2018-02-26 | 23546 |
| APO-CELECOXIB | 100MG | CAPSULE | Resolved | 2018-01-22 | 2018-04-02 | 36809 |
| APO-CEPHALEX | 500MG | TABLET | Resolved | 2022-12-09 | 2023-02-16 | 177678 |
| APO-CEPHALEX | 250MG | TABLET | Resolved | 2023-07-07 | 2024-01-12 | 197876 |
| APO-CEPHALEX | 500MG | TABLET | Resolved | 2023-11-10 | 2024-01-12 | 209930 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |